United States

People: Cidara Therapeutics Inc (CDTX.OQ)

CDTX.OQ on NASDAQ Stock Exchange Global Market

23 Mar 2018
Change (% chg)

$-0.05 (-0.93%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Bartizal, Kenneth 

Dr. Kenneth Bartizal, Ph.D is Chief Development Officer of the company. Since July 2014. From 2007 to 2013 he served as Chief Development Officer at Trius Therapeutics, Inc., a publicly-traded biopharmaceutical company, until its acquisition by Cubist Pharmaceuticals, Inc. From 1988 to 2007, Dr. Bartizal served as Executive Director and Head of Infectious Diseases at Merck & Co., Inc., a publicly-traded pharmaceutical company. From 1986 to 1988, Dr. Bartizal served as a research scientist at Pfizer Inc., a pharmaceutical company. From 1983 to 1986, he was a faculty member and conducted research at Kirksville College of Osteopathic Medicine and Northeast Missouri State University. Dr. Bartizal received his B.S., M.S. and Ph.D. degrees from the University of Notre Dame.

Basic Compensation

Total Annual Compensation, USD 213,937
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 121,478
Fiscal Year Total, USD 335,415

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --